| Document |
Document Title |
|
WO/2017/130687A1 |
[Problem] To make the size and shape of obtained particles uniform. Proposed is a mode by which the power cost is not increased. [Solution] A method of producing particles for which contact is brought about between a plurality of dissimi...
|
|
WO/2017/125673A1 |
The invention relates to a method for preparing a compound (I) or one of the salts thereof, and the uses of said method, R1OOC-C(=X)-CHR2 R3 (I), wherein X is selected among O; N-R', wherein R' is H or a C1-C6 alkyl; and N-OR'' wherein R...
|
|
WO/2017/122121A1 |
This present invention relates to a method of stabilizing an aqueous pharmaceutical preparation susceptible to degradation by formulating in a dual buffer system wherein the individual buffers are selected from phosphate, aspartate, glut...
|
|
WO/2017/117124A1 |
A crosslinkable hole transport molecule having four radical polymerizable groups to be used in a photoconductor to provide a medium for hole transport upon exposure to light and method to make the same is provided. Photoconductors using ...
|
|
WO/2017/113428A1 |
Disclosed are a method for synthesizing a number of aliphatic cyanoamino acids and application of the cyanoamino acids in bioorthogonal Raman detection. The aliphatic cyanoamino acids are methionine derivatives and lysine derivatives. Th...
|
|
WO/2017/114225A1 |
The present invention relates to a fused tricyclic γ-amino acid derivative and a pharmaceutical application thereof. Specifically, the present invention relates to a fused tricyclic γ-amino acid derivative depicted by general formula (...
|
|
WO/2017/107907A1 |
The present invention relates to a condensed ring γ-amino acid derivative and a medical use thereof, and in particular relates to the condensed ring γ-amino acid derivative as shown in formula (I), or a stereisomer, a solvate, a metabo...
|
|
WO/2017/108884A1 |
It is provided a compound of formula (I'); wherein R5 is selected from the group consisting of -H, -OM, -COOM, -NH2, -SO3M, (C1-C4)alkyl, and halogen; and A is a radical having at least 3 C atoms selected from the group consisting of: i)...
|
|
WO/2017/102483A1 |
Process for manufacturing a crystalline alkali metal salt of the general formula (I) [R1-CH(COO)-N(CH2-COO)2]M1 3 (I) wherein M1 is selected from alkali metal cations, same or different, R1 is selected from C1-C4-alkyl and CH2CH2COOM1, c...
|
|
WO/2017/105090A1 |
The present invention provides the Form 1 crystalline polymorph of L-carnitine orotate, a production method therefor, and a use thereof. The Form 1 crystalline polymorph of L-carnitine orotate of the present invention can be used as a ph...
|
|
WO/2017/106279A1 |
Personal care compositions, such as oral care and skin care compositions containing a flavor/perfume system comprising one or more coolants. The pleasant cool sensation provided by a coolant is enhanced in terms of quicker onset, greater...
|
|
WO/2017/097657A1 |
Process for manufacturing granules of at least one alkali metal salt of aminopolycarboxylic acid (A), comprising the steps of (a) providing an aqueous slurry of alkali metal salt of aminopolycarboxylic acid (A), (b) maintaining said aque...
|
|
WO/2017/093732A1 |
The invention relates to lipid compounds of formula (I) and their pharmaceutically acceptable salts for the prevention and/or treatment of ophthalmic disorders such as retinal degenerative disorders and ocular inflammatory diseases: (I) ...
|
|
WO/2017/089607A1 |
The invention relates to y-amaninamide (1; x = 0, 1 or 2), y-amaninamidic acid (2; x = 0, 1 or 2), and γ-amaninamidic hydroxamic acid (3; x = 0, 1 or 2), novel derivatives of γ-amanitin (4), and methods and novel building blocks for th...
|
|
WO/2017/088819A1 |
The present application relates to a preparation method of intermediate compounds with formula II and formula III of a compound (N-{3-[3-(9H-purin-6-yl) pyridin-2-ylamino]-4-chloro-2-fluorophenyl}-3-fluoropropane-
1-sulfonamide) for regu...
|
|
WO/2017/090354A1 |
[Problem] To provide an aromatic compound methylation method, in which a reaction substrate that serves as a raw material can be synthesized easily, and which can be employed as a method for producing a [11C]-labeled tracer for PET use. ...
|
|
WO/2017/090007A1 |
The compositions and compounds of formula I, formula II, formula III which includes a molecular conjugate with ornithine or its polymorphs, enantiomers, stereoisomers, solvates, and hydrates thereof. These salts may be formulated as phar...
|
|
WO/2017/087388A1 |
Phenyl cyclohexanone based active agents, pharmaceutical preparations containing such active agents, methods of modifying cellular activity by contacting cells with such active agents, and methods of treating various conditions by admini...
|
|
WO/2017/081206A1 |
The invention relates to an industrially viable and advantageous process for the preparation of (2S,3R)-2-amino-3-(3,4-dihydroxyphenyl)-3-hydroxypropanoic acid, having the following formula (I) generally known as Droxidopa, or of interme...
|
|
WO/2017/078927A1 |
Novel compounds having a formula (I), embodiments of a method of making the same, and of a composition comprising them are disclosed herein. Also disclosed are embodiments of a method of treating or preventing a metabolic disorder in a s...
|
|
WO/2017/079391A1 |
The present invention provides compounds of Formula I and Formula II, and related compositions and methods.
|
|
WO/2017/075531A1 |
Compounds are provided having the following structure: (I) or a pharmaceutically acceptable salt, tautomer or stereoisomer thereof, wherein R1, R2, R3, L1, L2, G1, G2 and G3 are as defined herein. Use of the compounds as a component of l...
|
|
WO/2017/070794A1 |
The present application relates to processes for the preparation of the aspergillomarasmine A (AM-A) compound and analogs and derivatives thereof. The features of this process involves the use of a cyclic activated serine synthon in the ...
|
|
WO/2017/065899A1 |
Described are deuterated chlorokynurenines and compositions, and their application as pharmaceuticals for the treatment of disease. Methods of modulating N-methyl-D-aspartate (NMDA) receptor activity, methods of treating disorders, inclu...
|
|
WO/2017/063491A1 |
Disclosed are a urea peptoid boric acid compound represented by formula (I), a pharmaceutical composition thereof, a preparation method therefor, and uses thereof. The compound can be used as a proteasome inhibitor to treat cancers.
|
|
WO/2017/062942A2 |
Cyclopentene carboxylic acid-related compounds as GAB A- AT inhibitors for treatment of various addictions, disorders and disease states.
|
|
WO/2017/051326A1 |
The invention relates to a novel process, novel process steps and novel intermediates useful in the synthesis of pharmaceutically active compounds, in particular neutral endopeptidase (NEP) inhibitors such as sacubitril, and prodrugs the...
|
|
WO/2017/049470A1 |
The present application discloses prodrugs of gamma-hydroxybutyric acid as well as compositions and uses thereof.
|
|
WO/2017/048528A1 |
Disclosed are a variety of amphoteric compounds containing a quaternary nitrogen group, a covalently bound counterion, and an ester or amide group. These amphoteric compounds can be advantageously prepared via a chemoenzymatic green proc...
|
|
WO/2017/045081A1 |
The present application is directed to transdermal formulations for the delivery of propionic and acetic acid NSAIDs to a subject for the treatment of NSAID- responsive diseases. In particular, the transdermal formulation is an emulsion ...
|
|
WO/2017/049245A2 |
The disclosure features novel lipids and compositions involving the same. Nanoparticle compositions include a novel lipid as well as additional lipids such as phospholipids, structural lipids, and PEG lipids. Nanoparticle compositions fu...
|
|
WO/2017/042700A1 |
The present invention provides solid forms comprising valsartan and sacubitril. The present invention provides solid salt forms comprising valsartan and sacubitril. The present invention further provides an amorphous solid salt form comp...
|
|
WO/2017/036934A1 |
The invention relates to a method for obtaining a carboxylic acid from a fermentation broth and to a system which is designed to carry out the method. The method has the following steps: a) separating the biomass from the fermentation br...
|
|
WO/2017/035631A1 |
The invention provides improved supplemental compositions, and methods for administering same to a user, for enhancing the onset, quality, and duration of sleep in humans and animals. The supplemental composition may contain a combinatio...
|
|
WO/2017/040805A1 |
The presently-disclosed subject matter relates to analyte-activated photolabile compounds. The compounds include the formula: wherein Z includes a maskable molecule; L is selected from a bond, C, C(O), O, alkyl, (O)alkyl, and alkoxy; R1 ...
|
|
WO/2017/021445A1 |
Tilidine isomerization and crystallization process, comprising providing a reaction mixture comprising cis-tilidine, a dicarboxylic acid, water and an alcohol having 3 to 6 carbon atoms; maintaining the reaction mixture at a temperature ...
|
|
WO/2017/021390A1 |
The present invention relates to the hemi sulfuric acid salt of methyl (R)-2-amino-2-(cyclohexa-1,4-dien-1-yl)acetate, also trivially referred to as the hemi sulfuric acid salt of D-dihydrophenylglycine methyl ester, to a method for the ...
|
|
WO/2017/024009A1 |
β-Substituted β-amino acids, β-substituted β-amino acid derivatives, and β-substituted β-amino acid analogs and (bio)isosteres and their use as chemotherapeutic agents are disclosed. The β-substituted β-amino acid derivatives and...
|
|
WO/2017/021385A1 |
The invention comprises a new process for the preparation of GalNAc derivatives of the formula I wherein n is an integer between 0 and 10 and its salts, corresponding enantiomers and/ or optical isomers thereof. The GalNAc acid derivativ...
|
|
WO/2017/012556A1 |
Disclosed are an aryl propionic acid compound and pharmaceutical use thereof. The present invention prepares a series of derivatives such as phosphate, sulfonate, carbonate, and amino acid esters by taking the most active alcohol metabol...
|
|
WO/2017/006573A1 |
A side chain precursor of paclitaxel and docetaxel is provided at high purity, high yield, and low cost through a method for producing a compound shown by formula (3) using a compound shown by formula (1) as a starting compound. Using th...
|
|
WO/2017/004706A1 |
The present invention relates to stable topical polymer matrix compositions comprising high concentrations (from about 1.5% w/w to about 3.5% w/w) sodium hyaluronate obtained from a Streptococcus zooepidemicus source and a non-ionic poly...
|
|
WO/2017/003483A1 |
The invention relates to polymorphic forms of the calcium salt of N-(3-carboxyl-1-oxopropyl)-(4S)-(p-phenylphenylmethyl)-4-ami
no-(2R)-methyl butanoic acid ethyl ester. The calcium salt of N-(3-carboxyl-1-oxopropyl)-(4S)-(p-phenylphenylm...
|
|
WO/2017/004052A2 |
Compounds, including chelated compounds, which may be used for the delivery of nutrients and micronutrients to plants are provided. In addition, processes for preparing such compounds, compositions comprising such compounds, and methods ...
|
|
WO/2017/002030A1 |
The present invention relates to stable, liquid parenteral formulations of Melphalan or pharmaceutically acceptable salts thereof. Further this invention also describes process of preparing such formulations.
|
|
WO/2016/202252A1 |
The present invention relates to the field of compound synthesis and discloses a method for synthesizing D-para-hydroxyphenylglycine methyl ester. The method comprises the steps of: (1) in the presence of thionyl chloride, carrying out a...
|
|
WO/2016/204376A1 |
Disclosed are novel intermediates for use in preparing DPP-IV inhibitors, methods for preparing the same, and methods for preparing DPP-IV inhibitors using the same. Using the novel intermediates of the present invention, highly pure DPP...
|
|
WO/2016/197580A1 |
The present invention discloses a method of synthesizing an α-amino acid derivative with α-alkyl side chain substitution. The method comprises: reacting an alkene with 9-bbn at 0-80˚C for 0.5-12 h, and then adding an imine to react at...
|
|
WO/2016/198322A1 |
The present invention relates to benzimidazol-2-amines of general formula (I), in which R1, R2, R3, R4, R5, R6, R7 and R8 are as defined herein, to methods of preparing said compounds, to intermediate compounds useful for preparing said ...
|
|
WO/2016/191872A1 |
Methods and compositions are provided for the treatment of familial exudative vitreoretinopathy (FEVR) through the administration of a therapeutically effective amount of a sphingosine-1-phosphate receptor type 2 (S1PR2) antagonist. Also...
|
